Dynamic Antibody Industry

Table of Contents

• INTRODUCTION
  • STUDY GOAL AND OBJECTIVES
  • CONTRIBUTION OF THE STUDY AND FOR WHOM
  • STUDY SCOPE AND FORMAT
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYSTS CREDENTIALS
  • RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
  • BCC ONLINE SERVICES
  • DISCLAIMER
• SUMMARY
  • Summary Table: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, THROUGH 2010 ($ MILLIONS)
  • Summary Figure: WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, 2002-2010 ($ MILLIONS)
• OVERVIEW
  • DEFINITIONS
    • DEFINITIONS (CONTINUED)
  • THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS
    • THE IMPORTANCE OF・CONTINUED)
  • INTELLECTUAL PROPERTY ISSUES/PATENT LICENSING
  • THE TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
  • Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
  • Table 1 (CONTINUED)
    • ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS
    • WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS AND POLYCLONAL ANTIBODY PRODUCTS DO NOT?
    • VALUATION OF ANTIBODY PRODUCT SALES
• TECHNOLOGY
  • OVERVIEW
    • OVERVIEW (CONTINUED)
    • THE HAMA PROBLEM AND ITS RESOLUTION
    • PHAGE DISPLAY AND POLYSOME DISPLAY
      • Phage Display and Polysome Display (Continued)
    • DIRECTED EVOLUTION
  • ANTIBODY CLASSES
  • ANTIBODY FORMS IN PRODUCTS
    • ABTIDES
    • ANTIBODY CONJUGATES
    • ANTISERUMS
    • BISPECIFIC ANTIBODIES
    • CAMOUFLAGED ANTIBODIES
    • CHIMERIC ANTIBODIES
    • FULLY HUMAN ANTIBODIES
    • HUMANIZED ANTIBODIES
    • PROGENITOR STEM CELLS
    • SINGLE-CHAIN ANTIBODIES
    • SYNTHETIC ANTIBODIES
  • SOURCES OF MONCLONAL ANTIBODIES ON THE MARKET
  • Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES
    • THE SPECIAL CASE OF ENBREL
    • ANTIBODY TECHNOLOGIES IN DEVELOPMENT
      • AFFIBODIES
      • DOMAIN ANTIBODIES
      • NANOBODIES
    • NEW DIRECTIONS IN ANTIBODY RESEARCH
    • THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS
    • THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS
    • THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS
  • Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS)
  • Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS)
    • THE TRANSGENIC ADVANTAGE
    • TRADITIONAL PRODUCTION METHODS
      • MICROBIAL FERMENTATION
      • MAMMALIAN CELL CULTURE
  • Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS
  • Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS
  • Table 6 (CONTINUED)
  • Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES
  • Table 7 (CONTINUED)
    • THE ENBREL SHORTAGE
    • THE CRUNCH IN CAPACITY
    • REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION
    • GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS
    • PRODUCTION OF ANTIBODIES IN ANIMALS
      • PRODUCTION OF ANTIBODIES・CONTINUED)
      • GOATS AS MONOCLONAL ANTIBODIES FACTORIES
      • CHICKENS AS MONOCLONAL ANTIBODIES FACTORIES
    • PRODUCTION OF ANTIBODIES IN PLANTS
      • PLASTIDS
      • TARGETING AND COMPARTMENTALIZING
      • TRANSGENIC SEEDS FOR ANTIBODY STORAGE
    • THE MARKET FOR TRANSGENICALLY PRODUCED ANTIBODY PRODUCTS
  • Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
  • Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
    • PLANTIBODIES IN DEVELOPMENT
  • Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE
  • Table 9 (CONTINUED)
    • ANTI-RABIES ANTIBODIES
    • CARORX
      • Carorx (Continued)
    • CLOSTRIDIUM DIFFICILE TOXIN A AND TOXIN B
    • OTHER THERAPEUTIC PLANTIBODIES IN DEVELOPMENT
    • TECHNOLOGY ISSUES WITH PLANT-BASED HUMAN ANTIBODIES
    • USING MONOCLONAL ANTIBODIES AS CARRIERS FOR CYTOTOXIC DRUGS
    • CONTRACT MANUFACTURING MARKET FOR BIOPHARMACEUTICALS GROWING
  • Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS)
    • CONTRACT MANUFACTURING MARKET・CONTINUED)
    • CONTRACT MANUFACTURING MARKET・CONTINUED)
• PRODUCTS
  • THE MARKET FOR POLYCLONAL AND MONOCLONAL ANTIBODY DRUGS
  • Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS)
  • Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS)
    • THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS
      • THE MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
  • Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
    • Sales by Technology
  • Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
  • Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS)
    • Sales by Target
  • Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
    • THE U.S. MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
  • Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS)
    • Marketed Products
  • Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET
  • Table 16 (CONTINUED)
    • THE EUROPEAN MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
  • Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS)
    • Marketed Products
  • Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET
    • Avastin
      • Avastin (Continued)
      • The Avastin Advantage
      • New Medicare Reimbursement Law Supports Use of Avastin
    • Bexxar
      • Bexxar (Continued)
    • Campath/MabCampath
    • Erbitux
  • Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
  • Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
    • Erbitux (Continued)
    • Herceptin
    • Humira
    • Mylotarg
    • Orthoclone OKT3
    • Panorex
    • Raptiva
    • Remicade
      • Remicade (Continued)
    • ReoPro
      • Reopro (Continued)
      • Reopro (Continued)
    • Rituxan/MabThera
      • Rituxan/Mabthera (Continued)
    • Simulect
    • Synagis
    • Tysabri (formerly Antegren)
    • Xolair
    • Zenapax
    • Zevalin
      • First Radioimmunotherapeutic Drug
      • Results of Trials
      • Sales of Zevalin
    • THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT
  • Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
    • Table 21 (CONTINUED)
      • ABT-874
      • AMG 108
      • AMG 162
        • AMG 714
      • Anti-CD20 Humanized Anticlonal Antibody
      • Anti-Tac(Fv)-PE38 Immunotoxin
      • Anti-TGF Beta
      • Avastin
      • CAL
      • Campath
      • Cantuzumab Mertansine
      • CAT-192
      • Cimzia (formerly CDP-870)
      • Cotara
      • Eculizumab
      • Erbitux
      • Felvizumab
      • Herceptin
      • HuMax-CD4
      • HuMax-CD20
      • HuMax-EGFr
      • HuMax-Inflam
      • Humira
      • HuN901-DM1
      • HuZAF
      • IMMU-102 and IMMU-103
      • Lucentis
      • LymphoStat-B
      • M200
      • MDX-010
      • MDX-018
      • MDX-060
      • MDX-070
      • Mepolizumab
      • MLN 02
      • MLN 1202
      • MLN 2704
      • Numax
      • Nuvion
      • Omnitarg
      • Osidem
      • OvaRex
      • Panitumumab
      • Pemtumomab
      • Pexelizumab
      • Pro70769
      • R1569
      • Remicade
      • Rituxan/MabThera
      • SGN-15
      • SGN-30
      • Synagis
      • TheraCIM hR3
      • Trabio
      • Tysabri
      • Vitaxin
      • Xolair
      • Zenapax
    • THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS
      • IMMUNOGLOBULINS
        • Intramuscular Products
        • Intravenous Products
      • NEW APPROACHES TO THE PRODUCTION OF HUMAN POLYCLONAL ANTIBODIES
      • THE MARKET FOR THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS
  • Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
    • MARKETED PRODUCTS
      • ATG-Fresenius S
      • BabyBIG
      • CytoGam
      • Flebogamma
      • Gamimune
      • Gamunex
      • Nabi-HB
      • Octagam
      • Rabies Immune Globulin
      • RespiGam
      • Tetanus Immune Globulin
      • Vaccinia Immune Globulin
      • Varicella-Zoster Immune Globulin
      • WinRho SDF Rho(D) Immune Globulin
      • Anti-Thymocyte Globulin
        • Atgam
        • Thymoglobulin
      • Antitoxins and Antivenins
        • CroFab
        • DigiFab
        • Diphtheria Antitoxin
        • ViperTAb
    • PRODUCTS IN DEVELOPMENT
  • Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  • Table 23 (CONTINUED)
    • Altastaph
    • ATG-Fresenius S
    • CytoFab
    • Nabi-HB Intravenous
    • Thymoglobulin
    • WinRho SDF
    • Early-Stage Products in Development
    • IN VIVO DIAGNOSTIC ANTIBODY PRODUCTS
  • Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
  • Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS)
    • MARKETED PRODUCTS
      • CEA-Scan
      • Humaspect
      • LeukoScan
      • MIBG
      • MyoScint
      • NeutroSpec
      • OctreoScan
      • ProstaScint
      • Verluma
    • PRODUCTS IN DEVELOPMENT
  • Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
  • Table 25 (CONTINUED)
    • AFP-Scan
    • Blood Tumor Antibody Diagnostics
      • Blood Tumor Antibody Diagnostics (Continued)
    • CEA-Scan
    • LeukoScan
    • LymphoScan
    • NeutroSpec
    • ProstaScint
    • Tru-Scint AD
    • Tru-Scint AG
• APPLICATIONS
  • LEADING THERAPEUTIC INDICATIONS OF APPROVED MONOCLONAL THERAPEUTIC ANTIBODY PRODUCTS
  • Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
  • Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%)
    • AUTOIMMUNE DISEASES
      • Crohns Disease
      • Psoriasis
      • Rheumatoid Arthritis
      • Antibody Products on the Market for the Treatment of Autoimmune Diseases
  • Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    • Antibodies in Development for the Treatment of Autoimmune Diseases
  • Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  • Table 28 (CONTINUED)
  • Table 28 (CONTINUED)
    • CANCER
      • U.S. Cancer Statistics
  • Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED)
  • Table 30 CANCER PREVALENCE RATES: U.S., 2000
  • Table 30 (CONTINUED)
    • Breast Cancer
    • Colorectal Cancer
    • Head and Neck Cancer
    • Kidney Cancer
    • Leukemias
      • Leukemias (Continued)
    • Liver Cancer
    • Lung Cancer
    • Malignant Melanoma
    • NonHodgkins Lymphoma
    • Osteosarcoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Stomach Cancer
    • Antibody Products on the Market for the Treatment of Cancer
  • Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
    • Antibodies in Development for the Treatment of Cancer
  • Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS
  • Table 32 (CONTINUED)
  • Table 32 (CONTINUED)
  • Table 32 (CONTINUED)
    • CARDIOVASCULAR DISEASES
  • Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002
  • Table 33 (CONTINUED)
    • Percutaneous Transluminal Coronary Angioplasty
    • Antibody Products on the Market for the Treatment of Cardiovascular Disease
    • Antibodies in Development for the Treatment of Cardiovascular Diseases
  • Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
    • INFECTIOUS DISEASES
      • Infectious Diseases (Continued)
      • Cytomegalovirus Infection
      • Hepatitis
      • Respiratory Syncytial Virus Infection
      • Antibodies on the Market for the Treatment of Infectious Diseases
      • Antibodies in Development for the Treatment of Infectious Diseases
  • Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES
  • Table 35 (CONTINUED)
    • OPHTHALMIC DISEASES
      • Macular Degeneration
    • ORGAN TRANSPLANT REJECTION AND GRAFT-VERSUS-HOST DISEASE
      • Organ Transplant Market Size
  • Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004
    • Antibody Products on the Market for the Treatment of Organ Transplant Rejection
  • Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION
    • Antibodies in Development for Organ Transplant Rejection
  • Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION
    • Bone Marrow and Stem Cell Transplantation/Graft-Versus-Host Disease
  • Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004
    • RESPIRATORY DISEASES
      • Allergic Rhinitis and Asthma
      • Allergic Rhinitis and Asthma (Continued)
        • Antibody Products on the Market for the Treatment of Allergic Rhinitis and Asthma
        • Antibodies in Development for the Treatment of Allergic Rhinitis and Asthma
  • Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA
    • OTHER THERAPEUTIC APPLICATIONS
  • Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES
    • DIAGNOSTIC IMAGING APPLICATIONS
      • IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN DEVELOPMENT FOR SELECTED INDICATIONS
  • Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS
• INDUSTRY STRUCTURE
  • ORIGINATORS
  • COMMERCIAL DEVELOPERS
  • VENDORS
  • MANUFACTURERS
  • TECHNOLOGY INNOVATORS
  • PRICING FORECASTS
  • PARTNERSHIPS ABOUND
  • Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004
  • Table 43 (CONTINUED)
    • THE REGULATORY ENVIRONMENT
      • THE REGULATORY ENVIRONMENT (CONTINUED)
    • MARKET SHARE OF MONOCLONAL ANTIBODY PRODUCT MANUFACTURERS
  • Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%)
  • Figure 6 (CONTINUED)
    • GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS
      • GENOMICS AND MONOCLONAL・CONTINUED)
      • GENOMICS AND MONOCLONAL・CONTINUED)
• COMPANY PROFILES
  • ABGENIX, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
      • XenoMouse and XenoMax Technologies
        • Xenomouse And Xenomax・Continued)
      • Technology Advantages
        • Technology Advantages (Continued)
    • CORPORATE STRATEGY
  • AMGEN, INC.
    • BUSINESS OVERVIEW
    • FINANCIAL INFORMATION
    • PRODUCTS
  • Table 44 AMGENS MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • BIOGEN IDEC, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
        • Corporate Strategy (continued)
    • CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
      • BUSINESS OVERVIEW
      • PRODUCTS
      • CORPORATE STRATEGY
    • CORIXA CORP.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • CYTOGEN CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • GENENTECH, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
  • Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
  • Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
    • GENMAB A/S
      • BUSINESS OVERVIEW
      • PRODUCTS
      • CORPORATE STRATEGY
    • GENZYME CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 47 GENZYMES MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • GTC BIOTHERAPEUTICS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS AND TECHNOLOGIES
        • Products and Technologies (Continued)
        • Monoclonal Antibodies (MAB) and Immunoglobulin (Ig) Fusion Proteins
      • CORPORATE STRATEGY
        • Corporate Strategy (Continued)
        • Corporate Strategy (Continued)
    • IMMUNOMEDICS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 48 IMMUNOMEDICS PRODUCT PIPELINE
  • Table 48 (CONTINUED)
    • CORPORATE STRATEGY
    • MEDAREX, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 49 MEDAREXS PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • MEDIMMUNE, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • LEADING PRODUCTS
  • Table 50 MEDIMMUNES MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • MILLENNIUM PHARMACEUTICALS, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 51 MILLENNIUMS MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • NABI BIOPHARMACEUTICALS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 52 NABI BIOPHARMACEUTICALS PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • PLANET BIOTECHNOLOGY, INC.
      • BUSINESS OVERVIEW
      • PRODUCTS AND TECHNOLOGY
        • Products and Technology (Continued)
        • CaroRx
        • RhinoRx
        • DoxoRx
    • PROTEIN DESIGN LABS
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 53 PROTEIN DESIGN LABS MONOCLONAL ANTIBODY PRODUCT PIPELINE
    • CORPORATE STRATEGY
    • PROTHERICS PLC
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • SYMPHOGEN A/S
      • BUSINESS OVERVIEW
      • PRODUCTS
  • Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES
    • CORPORATE STRATEGY
    • TRANXENOGEN, INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS AND TECHNOLOGY
      • CORPORATE STRATEGY
    • VIREXX MEDICAL CORPORATION
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • XOMA LTD.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
      • CORPORATE STRATEGY
    • YM BIOSCIENCES INC.
      • BUSINESS OVERVIEW
      • FINANCIAL INFORMATION
      • PRODUCTS
  • Table 55 YM BIOSCIENCES PRODUCT PIPELINE
    • CORPORATE STRATEGY
•  
• LIST OF TABLES
• Summary Table:
• Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
• Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES
• Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS)
• Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS)
• Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS
• Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS
• Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES
• Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
• Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE
• Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS)
• Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS)
• Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
• Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
• Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS)
• Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET
• Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS)
• Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET
• Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
• Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
• Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
• Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
• Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
• Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
• Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
• Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES
• Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED)
• Table 30 CANCER PREVALENCE RATES: U.S., 2000
• Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
• Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS
• Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002
• Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
• Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES
• Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004
• Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION
• Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION
• Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004
• Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA
• Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES
• Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS
• Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004
• Table 44 AMGENS MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
• Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
• Table 47 GENZYMES MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 48 IMMUNOMEDICS PRODUCT PIPELINE
• Table 49 MEDAREXS PRODUCT PIPELINE
• Table 50 MEDIMMUNES MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 51 MILLENNIUMS MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 52 NABI BIOPHARMACEUTICALS PRODUCT PIPELINE
• Table 53 PROTEIN DESIGN LABS MONOCLONAL ANTIBODY PRODUCT PIPELINE
• Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES
• Table 55 YM BIOSCIENCES PRODUCT PIPELINE
• LIST OF FIGURES
• Summary Figure:
• Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
• Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS)
• Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS)
• Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS)
• Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%)
• Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%)